Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2386 to 2400 of 7681 results

  1. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

    Awaiting development [GID-TA10757] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    Medical technologies guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for MTG12

  7. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

    Technology appraisal guidance
    Topic selection

  8. The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)

    Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

    Medical technologies guidance
    Last updated
    25 March 2019
    View recommendations

    Sections for MTG17

  9. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  10. The geko device for reducing the risk of venous thromboembolism (MTG19)

    Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.

    Medical technologies guidance
    Published
    25 June 2014
    View recommendations

    Sections for MTG19

  11. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (MTG22)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

    Medical technologies guidance
    Last updated
    1 March 2015
    View recommendations

    Sections for MTG22

  12. Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]

    In development [GID-TA11397] Expected publication date: 26 February 2025

    Technology appraisal guidance
    In development

  13. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    Awaiting development [GID-TA11468] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

    In development [GID-TA10620] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development [GID-TA10971] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development